| Literature DB >> 35615625 |
F Bruschi1, D S Ashour2, A A Othman2.
Abstract
Trichinella spiralis is a unique parasite in that both the adults and larvae survive in two different intracellular niches in the same host. The immune response, albeit intense, is highly modulated to ensure the survival of both the host and the parasite. It is skewed to T helper 2 and regulatory arms. Diverse cells from both the innate and adaptive compartments of immunity, including dendritic cells, T regulatory cells, and alternatively activated macrophages are thought to mediate such immunomodulation. The parasite has also an outstanding ability to evade the immune system by several elaborate processes. The molecules derived from the parasites including Trichinella, particularly the components of the excretory-secretory products, are being continually identified and explored for the potential of ameliorating the immunopathology in animal models of diverse inflammatory and autoimmune human diseases. Herein we discuss the various aspects of Trichinella-induced immunomodulation with a special reference to the practical implications of the immune system manipulation in alleviating or possibly curing human diseases.Entities:
Keywords: AAM, alternatively activated macrophage; AW, adult worm; Allergy; Autoimmune diseases; Breg, regulatory B cell; CAM, classically activated macrophage; Cancer; ES L1, ES product of T. spiralis muscle larva; ES, excretory–secretory; IFN- γ, interferon-γ; IIL, intestinal infective larva; IL, interleukin; Immune evasion; Immunomodulation; ML, muscle larva; NBL, newborn larva; NOS, nitric oxide synthase; TGF-β, transforming growth factor-β; TLR, toll-like receptor; TNF- α, tumor necrosis factor-α; Th, T helper; Tol-DC, tolerogenic dendritic cell; Treg, regulatory T cell; Trichinella; Trichinella-derived molecules; Ts-AES, ES from adult T. spiralis
Year: 2022 PMID: 35615625 PMCID: PMC9125654 DOI: 10.1016/j.fawpar.2022.e00164
Source DB: PubMed Journal: Food Waterborne Parasitol ISSN: 2405-6766
Key effector players during Trichinella infection
| Effector | Function(s) |
|---|---|
| CD4+ Th2 cells | Secretion of cytokines to trigger all adaptive Th2 immune responses |
| ILC2 | Release of several type 2 cytokines |
| Mast cells/Basophils | Release of mediators that mediate intestinal inflammation |
| Goblet cells | Secretion of mucus that help trap the parasites |
| Eosinophils | Role controversial; release of toxic products and cytokines; ADCC |
| Macrophages | Release of mediators; smooth muscle contraction |
| IL-4 | IgE production and transport; goblet cell stimulation; eosinophil activation |
| IL-5 | Recruitment and activation of eosinophils |
| IL-13 | Goblet cell proliferation and differentiation; stimulation of smooth muscle contraction; migration and activation of DCs |
| IgE | ADCC |
| CD4+ Th2 cells | Release of type 2 cytokines |
| Inflammatory cells | Present around nurse cells but fail to eliminate the larvae |
| Antibodies (IgG1, IgE) | Increased in serum; do not affect muscle larvae |
Data compiled from several sources (Bruschi and Dupouy-Camet, 2014; Grencis et al., 2014; Fabre et al., 2009; Sorobetea et al., 2018). ADCC: antibody-dependent cellular cytotoxicity; ILC: innate lymphoid cells; DCs: dendritic cells.
Fig. 1Trichinella-induced immunomodulation of various human disorders.
ES L1: ES product of T. spiralis muscle larvae; AES: ES from adult T. spiralis; Treg: regulatory T cell; Breg: regulatory B cell; AAM: alternatively activated macrophage; Tol-DC: tolerogenic dendritic cell; IBD: inflammatory bowel disease; RA: rheumatoid arthritis; MS: multiple sclerosis; T1DM: Type 1 diabetes mellitus.
T. spiralis molecules with potential regulatory functions
| Localization in the parasite | Function(s) | Regulatory mechanism(s) | |
|---|---|---|---|
| TGF-β ligand homologue from | Widely distributed in most metazoans ( | Participation in many biological processes such as development and immunoregulation ( | TGF- |
| Identified in β-stichocytes of the stichosome and in the ES-L1 of | Protease inhibition and immunomodulation ( | Downregulation of pro-inflammatory cytokines, NOS II and CAMs markers and | |
| ES antigens of | Host cell invasion, tissue migration, immune modulation/suppression, and parasite survival in the host ( | Induction of AAMs macrophages ameliorating intestinal injury in intestinal ischemia/reperfusion model ( | |
| Somatic proteins of | Detoxification enzyme essential for development and survival of the parasite and infective larval invasion ( | Decrease of the LPS-induced elevated level of pro-inflammatory cytokines of dendritic cells and enhancement of the level of regulatory cytokines IL-10 and TGF- β ( | |
| Somatic antigen of all the stages of | Immune evasion and survival in host by inhibition of C1q-initiated complement classical activation pathway ( | Immunomodulatory protein to neutralize C1q-induced complement activation ( | |
| ES antigen of | Involved in many biological activities and evasion of host immunity ( | Activation of tolerogenic DC phenotype and polarization of T cells towards Th2 and induction of anti-inflammatory responses (increase IL-10 production) ( |
AW = adult worm; IIL = intestinal infective larva; ML = muscle larva.
T. spiralis proteins with potential anti-tumor effects
| Protein | Localization | Function(s) | Anti-tumor mechanism(s) |
|---|---|---|---|
| Caveolin-1 (cav-1) | On the surface of | Oocyte maturation and embryogenesis during development, with a gender-specific expression ( | Tumor suppression by inducing cell cycle arrest and apoptosis ( |
| Heat shock proteins 70 (TS- HSP70) | Somatic and ES antigen of | Involvement in several biological processes such as invasion of host tissue, larval migration or molting, immune modulation and metabolic processes ( | Acting as potent immunoadjuvants that can provoke more powerful anti-tumor |
| Retinoblastoma binding protein 4 (Rbbp4) | Expressed in myeloma cells in the presence of | Retinoblastoma protein is a potent regulator of cellular proliferation, control chromatin cohesion, chromatin structure and tumor proliferation and differentiation. It is involved in inhibiting breast cancer MCF 7 cell growth ( | |
| Natural killer cell triggering receptor (NKTR) protein from | Expressed in myeloma cells in the presence of | Induction of cytotoxic NK cells in the tumor microenvironment with anti-tumor activity in a B-cell lymphoma model ( | |
| Cytoskeletal protein ( | A component of | Anti-tumor activity in the myeloma cell line SP2/0 ( | |
| c-Ski | An oncoprotein expressed in | A co-repressor protein that turns off the transcription, and results in cell cycle arrest and transformation of | Production of tumor growth inhibiting cytokines such as TGF-β ( |